REG - Novacyt S.A. - Rule 19.6(c) confirmation of post-offer intentions

Novacyt SAAnnouncement

20/09/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240920:nRST1183Fa&default-theme=true

RNS Number : 1183F  Novacyt S.A.  20 September 2024

THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULE
19.6(C) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE"), WHICH, INTER
ALIA, REQUIRES A PARTY TO AN OFFER TO MAKE AN ANNOUNCEMENT AT THE END OF A
PERIOD OF 12 MONTHS FROM THE DATE ON WHICH THE OFFER PERIOD ENDED CONFIRMING
WHETHER IT HAS TAKEN, OR NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED
INTENTIONS

FOR IMMEDIATE RELEASE

20 September 2024

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Rule 19.6(c) confirmation in respect of post-offer intention statements made
in relation to Yourgene Health plc ("Yourgene")

 

Novacyt announces that, further to the completion of its recommended cash
offer for the entire issued and to be issued share capital of Yourgene, which
was implemented by way of a scheme of arrangement under Part 26 of the
Companies Act 2006 and which became effective on 8 September 2023, it has duly
confirmed in writing to The Panel on Takeovers and Mergers in accordance with
the requirements of Rule 19.6(c) of the Code that Novacyt has complied with
their respective post-offer intention statements made pursuant to Rules
2.7(c)(viii) and 24.2 of the Code, as detailed in its announcement of 3 July
2023 and scheme document published on 27 July 2023.

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Stephanie Cuthbert / Paul McManus /                                     +44 (0)7796 794 663 / +44 (0)7980 541 893

 Phillip Marriage / Alice Woodings                                        +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical           Broad portfolio of human clinical in vitro diagnostic products, workflows and
                    services focused on three therapeutic areas:

                    ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                    tests

                    ·    Precision Medicine: DPYD genotyping assay

                    ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                    panel

 Instrumentation    Portfolio of next generation size selection DNA sample preparation platforms
                    and rapid PCR machines, including:

                    ·    Ranger® Technology: automated DNA sample preparation and target
                    enrichment technology

                    MyGo: real-time quantitative PCR (qPCR) instruments

 Research Use Only  Range of services for the research industry:

                    ·    Design, manufacture, and supply of high-performance qPCR assays and
                    workflows for use in human health, agriculture, veterinary and environmental,
                    to support global health organisations and the research industry

                    ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                    whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy in France with offices in the UK (in
Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and
has a commercial presence in over 65 countries. The Company is listed on the
London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange
Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQQKKBKABKDNCB